What it's for (Indications)
- Travoprost is primarily indicated for the reduction of elevated intraocular pressure (IOP) in adult patients diagnosed with open-angle glaucoma or ocular hypertension.
- Open-angle glaucoma, a chronic and progressive optic neuropathy, is characterized by damage to the optic nerve and corresponding visual field loss, often directly associated with sustained elevated IOP.
- Ocular hypertension, conversely, signifies elevated IOP without concomitant signs of optic nerve damage or visual field defects.
- The clinical imperative for using travoprost in these conditions is to achieve and maintain a significant and sustained reduction in IOP, thereby preventing the progression of optic nerve damage and the subsequent, irreversible loss of visual acuity and field.
- Travoprost may be employed as monotherapy, representing a first-line therapeutic option in many clinical settings, or as an adjunctive therapy when other IOP-lowering medications prove insufficient in achieving target IOP, or when patients experience intolerable side effects from alternative treatments.
- Its established efficacy in consistently lowering IOP makes it a critical component in the long-term management strategy aimed at preserving ocular health and visual function in affected individuals, requiring strict adherence to prescribed regimens for optimal therapeutic outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage is one drop in the affected eye(s) once daily in the evening. Travoprost ophthalmic solution should not be administered more than once daily, as more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect. Reduction of IOP starts approximately 2 hours after the first administration, with maximum effect reached after 12 hours. If used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, the drugs should be administered at least five (5) minutes apart. |
Safety & Warnings
Common Side Effects
- The most common adverse reaction (reported in 30% to 50% of patients) is ocular/conjunctival hyperemia (redness of the eyes).
- Other reported ocular adverse reactions (5% to 10% incidence) include decreased visual acuity, eye discomfort, and foreign body sensation.
- Patients may also experience iris hyperpigmentation (darkening of the colored part of the eye), eye pain, irritation, itchiness, dryness, photophobia, keratitis, flare headache, and darkening of periorbital skin and eyelids.
- Up to 3% of patients discontinued therapy due to conjunctival hyperemia.
Serious Warnings
- Black Box Warning: While travoprost ophthalmic solution (e.g., Travson) does not carry a formal FDA Black Box Warning, several serious considerations and potential adverse effects warrant comprehensive attention from both prescribing healthcare professionals and patients. Therefore, the following 'Serious Warnings' section is provided: **Serious Warnings** 1. **Permanent Iris Pigmentation Change:** Travoprost may cause a gradual and potentially permanent increase in the brown pigmentation of the iris. This change is irreversible and is more frequently observed in patients with mixed-color irides (e.g., blue-brown, grey-brown, yellow-brown, green-brown). Patients receiving treatment in only one eye should be counselled on the potential for asymmetric eye color changes, which may be cosmetically significant. 2. **Eyelid and Eyelash Changes:** Treatment with travoprost can lead to increased pigmentation of the periocular skin (eyelid darkening) and alterations in eyelashes, including increased length, thickness, pigmentation, and/or number of eyelashes. While eyelid skin darkening and eyelash changes are generally reversible upon discontinuation of the medication, patients should be informed of these potential cosmetic alterations. 3. **Intraocular Inflammation:** Travoprost should be used with extreme caution in patients with a history of, or active, intraocular inflammation (e.g., iritis, uveitis). Prostaglandin analogs have the potential to exacerbate these inflammatory conditions, leading to increased pain, redness, photophobia, and potential vision loss. Regular and diligent monitoring for signs of inflammation is strongly recommended throughout therapy, and discontinuation may be necessary if exacerbation occurs. 4. **Macular Edema:** Cystoid macular edema (CME), including its exacerbation, has been reported during treatment with prostaglandin analogs, including travoprost. This risk is particularly elevated in aphakic patients, pseudophakic patients with a torn posterior lens capsule, and individuals with known risk factors for macular edema. Ophthalmologic examination and vigilance for any vision changes, such as decreased visual acuity or distorted vision, are essential for such susceptible individuals. 5. **Bacterial Keratitis:** As with all multi-dose ophthalmic products, the potential for contamination of the solution by bacteria from contact with various surfaces (e.g., hands, eyelids, eyelashes) exists. Such contamination can lead to bacterial keratitis, a severe ocular infection that may cause serious damage to the eye, corneal ulceration, and subsequent vision loss. Patients must be meticulously instructed on proper administration technique, including avoiding contact between the dropper tip and the eye or any other surface, to minimize this significant risk.
- Pregnancy: Risk cannot be ruled out for use during pregnancy; contraception must be used while taking this medication.
- Lactation: This medicine is contraindicated in nursing females.
- Driving: Patients should avoid driving if vision is affected by the medicine.
- Skin Contact: Avoid direct skin contact.
- Eye Changes: Patients should be warned of possible permanent changes in eye color (iris hyperpigmentation) and darkening of periorbital skin and eyelids.
- Ocular Conditions: Observe eye condition closely, especially in patients with dry eyes or compromised corneas.
- Caution is advised in patients suffering from aphakia (absence of natural eye lens), pseudophakia (degeneration of lens), cystoid macular edema (disorder of the retina causing buildup of fluid), iritis (inflammation of the colored part of the eye), active eye inflammation, thyroid eye disease, neovascular glaucoma, angle-closure glaucoma, congenital glaucoma, pigmentary glaucoma, or pseudoexfoliative glaucoma.
- Contact Lenses: Remove contact lenses before administering the medication and wait for at least 15 minutes before reinserting them.
How it Works (Mechanism of Action)
Travoprost free acid, a prostaglandin analog, is a selective FP prostanoid receptor agonist which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Commercial Brands (Alternatives)
No other brands found for this formula.